290 related articles for article (PubMed ID: 32476507)
1. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
Megna M; Cinelli E; Camela E; Fabbrocini G
Expert Rev Clin Immunol; 2020 Jun; 16(6):599-620. PubMed ID: 32476507
[TBL] [Abstract][Full Text] [Related]
2. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.
Paul C; Bang B; Lebwohl M
Expert Opin Pharmacother; 2017 Jan; 18(1):115-121. PubMed ID: 27936972
[TBL] [Abstract][Full Text] [Related]
3. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
Foley P; Garrett S; Ryttig L
Curr Med Res Opin; 2018 Jul; 34(7):1277-1283. PubMed ID: 29336190
[TBL] [Abstract][Full Text] [Related]
5. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
[TBL] [Abstract][Full Text] [Related]
7. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
Kragballe K; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():10-21. PubMed ID: 24684739
[TBL] [Abstract][Full Text] [Related]
8. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
[TBL] [Abstract][Full Text] [Related]
9. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.
McCormack PL
Drugs; 2011 Apr; 71(6):709-30. PubMed ID: 21504248
[TBL] [Abstract][Full Text] [Related]
10. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
[TBL] [Abstract][Full Text] [Related]
12. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
Fabbrocini G; Dauden E; Jalili A; Bewley A
G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
14. Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
Takeoka S; Shimizu T; Kamata M; Hau CS; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol; 2020 Feb; 47(2):155-162. PubMed ID: 31762070
[TBL] [Abstract][Full Text] [Related]
15. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
[TBL] [Abstract][Full Text] [Related]
16. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
Lambert J; Hol CW; Vink J
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2349-55. PubMed ID: 26337069
[TBL] [Abstract][Full Text] [Related]
17. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis.
Amat-Samaranch V; Puig L
Expert Opin Drug Saf; 2020 Apr; 19(4):423-432. PubMed ID: 32243212
[No Abstract] [Full Text] [Related]
18. Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation.
Purvis CG; Balogh EA; Heron CE; Feldman SR
Expert Opin Pharmacother; 2021 Jun; 22(9):1107-1118. PubMed ID: 33745399
[No Abstract] [Full Text] [Related]
19. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
[TBL] [Abstract][Full Text] [Related]
20. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris.
Queille-Roussel C; Nielsen J; Lacour JP
J Dermatolog Treat; 2019 Sep; 30(6):529-533. PubMed ID: 30582717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
